Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

NCT04189848 on ClinicalTrials.gov · last registry update 2022-11-07

Finished 29 January 2020, after enrolling 104 people. Primary outcome, as filed: Intensity of Injection Site Pain. semaglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 104
Started: 2019-12-03
Primary completion: 2020-01-29 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Intensity of Injection Site Pain

Conditions studied

Healthy Volunteers · Diabetes Mellitus, Type 2 · Overweight · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.